<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1451">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04487886</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000701</org_study_id>
    <nct_id>NCT04487886</nct_id>
  </id_info>
  <brief_title>Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)</brief_title>
  <acronym>DAMPEN-CI</acronym>
  <official_title>Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, a total of 80 patients with severe coronavirus disease 2019 (COVID-19)
      infection will be randomized to receive Duvelisib or a placebo. Participants will be enrolled
      at Emory University Hospital and at the University of Pennsylvania and will be identified and
      recruited by their treating physician and research team.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized placebo-controlled phase 2 study will evaluate whether a two-week exposure to
      duvelisib, a gamma/delta phosphoinositide 3-kinase (PI3K) inhibitor, reduces inflammation in
      the lungs in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
      infection and COVID-19 who do not require mechanical ventilation at study initiation. The
      primary objective of the study is to determine the efficacy of duvelisib treatment in
      preventing death or the need for mechanical ventilation among patients with World Health
      Organization (WHO)-defined severe COVID-19. Key secondary endpoints will be reductions in
      oxygen requirements of patients and improvements in their performance status, safety and
      tolerability of duvelisib in the setting of COVID-19, biomarkers of inflammation, duration of
      viremia, and generation of immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody
      responses to SARS-Cov-2 spike protein. The study will determine if a two-week exposure to
      duvelisib beginning soon after presentation with severe COVID-19 warrants further evaluation
      in a larger clinical study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Requiring Mechanical Ventilation or Dying</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>This is a composite endpoint of the number of participants who require mechanical ventilation or who die within four weeks of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days to Recovery</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Time to recovery (in days) is defined as a score of greater than 5 from the following eight categories from the NIAID ordinal scale. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized, limitation on activities and/or requiring home oxygen; 8. Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>The number of days spent hospitalized will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Death</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>The incidence of death within 29 days of randomization will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Transferred to ICU</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Comparing the proportion of subjects in each group requiring ICU transfer within 29 days of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score</measure>
    <time_frame>Day 15, Day 29</time_frame>
    <description>The ECOG Performance Status instrument includes a single item assessing overall physical status. Health status is rated on a scale of 0 to 5 where 0 = fully active and 5 = dead. Median ECOG performance will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade III-V Adverse Events</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>The incidence of grade III-V adverse events or Serious Adverse Events (SAEs), as defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5, will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Secondary Bacterial or Viral Infections</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>The incidence of documented secondary bacterial or viral infections among participants will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Th1 T Cell Frequency</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>The mean frequency of Th1 T cells in blood mononuclear cells will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Th17 T Cell Frequency</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>The mean frequency of Th17 T cells in blood mononuclear cells will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-2 (IL-2)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker IL-2 will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-2 receptor (IL-2R)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker IL-2R will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-6 (IL-6)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker IL-6 will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-7 (IL-7)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker IL-7 will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-8 (IL-8)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker IL-8 will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-10 (IL-10)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker IL-10 will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interferon gamma-induced Protein 10 (IP-10)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker IP-10 will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Macrophage Inflammatory Protein 1alpha (MIP-1a)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker MIP-1a will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Monocyte Chemoattractant Protein-1 (MCP-1)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker MCP-1 will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Granulocyte Colony-stimulating Factor (G-CSF)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker G-CSF will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Necrosis Factor (TNF)-alpha</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the inflammatory serum biomarker TNF-alpha will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vasoactive Intestinal Peptide (VIP)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>VIP is a peptide hormone with immunosuppressive properties. Mean levels VIP will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gene Expression Profile of Regulatory T Cells (Tregs)</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of the Tregs will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gene Expression Profile of cluster of differentiation 8 (CD8)+Interferon Gamma (IFNg)+ Granulocyte-macrophage colony-stimulating factor (GM-CSF)+</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of CD8+IFNg+GM-CSF+ will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gene Expression Profile of CD8+ T cell immunoglobulin and mucin domain-containing protein 3 (Tim3)+ Programmed cell death protein 1 (PD-1)+</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of CD8+Tim3+PD-1+ will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gene Expression Profile of cluster of differentiation 14 (CD14)+ cluster of differentiation (CD16)+ monocytes</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of CD14+CD16+ monocytes will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SARS-CoV-2 Viremia</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Mean levels of SARS-CoV-2 viremia in respiratory specimens will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Immunoglobulin G (IgG) Antibodies</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Median titers of IgG antibodies to SARS-CoV-2 will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Immunoglobulin M (IgM) Antibodies</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
    <description>Median titers of IgM antibodies to SARS-CoV-2 will be compared between study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Overall survival is defined as days from randomization to death and censored at last follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Duvelisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive duvelisib for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive a placebo to match duvelisib for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.</description>
    <arm_group_label>Duvelisib</arm_group_label>
    <other_name>Copiktra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo to match duvelisib will be taken orally twice per day for 14 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized in participating facility.

          -  Documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g.,
             chest x-ray or CT scan).

          -  Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction
             (PCR) or other authorized or approved assay in any specimen collected within 72 hours
             prior to enrollment. Note - An exception must be requested to the Sponsor if â‰¥72 hours
             since positive test.

          -  Symptoms suggestive of severe systemic illness with COVID-19, such as respiratory rate
             &gt; 30 breaths per minute, heart rate &gt;125 beats per minute, oxygen saturation (O2 sat)
             in the blood of &lt;93% on room air at sea level or the ratio of arterial oxygen partial
             pressure to fractional inspired oxygen (PaO2/FiO2)&lt; 300

          -  18 years of age or older

          -  Patients with hematological parameters at screening consistent with &lt; grade 2 NCI
             CTCAE v5.0 toxicity: hemoglobin &gt;8 g/dL, platelet count &gt;50,000 K/mcl, an absolute
             neutrophil count (ANC) &gt;1,000/mm3, and an absolute lymphocyte count (ALC) &gt;500/mm3.

          -  Patients with laboratory measurements of liver function at screening consistent with &lt;
             grade 2 NCI CTCAE v5.0 toxicity: alanine aminotransferase (ALT) &lt; 5 times the upper
             limit of normal (ULN); aspartate aminotransferase (AST) &lt; 5 times ULN; and bilirubin &lt;
             3 times ULN.

          -  The effects of duvelisib on the developing human fetus are unknown. For this reason,
             women of child-bearing potential (WOCBP) must have a negative serum or urine
             pr5egnancy test prior to starting therapy. WOCBP and men must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) from
             enrollment into this study until at least 60 days after the first dose of duvelisib. A
             woman of childbearing potential (WOCBP) is a sexually mature woman who: 1) has not
             undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
             postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in
             the preceding 24 consecutive months. Should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately. Men treated or enrolled on this protocol must also
             agree to use adequate contraception prior to the study, for the duration of study
             participation, and 2 months after completion of duvelisib administration. WOCBP must
             have a negative pregnancy test within 24 hours of the first dose of duvelisib.

          -  The patient must be willing to comply with fertility requirements as below:

               -  Total abstinence (when this is in line with the usual practice and lifestyle of
                  the patient) will be accepted. Periodic abstinence (i.e., calendar, ovulation,
                  post-ovulation methods) and withdrawals are not acceptable forms

               -  If a female participant is of reproductive potential, the participant (and her
                  partner) must agree to use of one of the following combinations of birth control
                  during the study and for 2 months after the last dose of study drug (or tubal
                  ligation as a single method):

                    -  Use of a double-barrier method of contraception: condoms (male or female)
                       and a diaphragm or cervical cap with spermicide;

                    -  Use of an IUD and a barrier method: condoms (male or female, with or without
                       spermicide) or a diaphragm or cervical cap with spermicide;

                    -  Tubal ligation.

               -  Women who are post-menopausal, defined as age greater than 45 and no menses for
                  at least 24 consecutive months, or who have had a hysterectomy, are considered
                  not of reproductive potential.

               -  Males must agree to using contraception during the study and for 2 months after
                  the last dose of study drug or have undergone a male sterilization procedure (at
                  least 6 months prior to screening.

               -  Use of oral (estrogen and progesterone), injected or implanted hormonal methods
                  of contraception, or placement of an intrauterine device (IUD) or intrauterine
                  system (IUS) or other forms of contraception that comparable efficacy (failure
                  rate &lt;1%). In case of oral contraception, the woman should be stable on the same
                  pill for a minimum of 3 months prior to enrollment on the study.

          -  Patients must agree not to donate blood, sperm/ova or any other organs while taking
             protocol therapy and for at least 2 weeks after stopping treatment.

          -  Willingness and ability of the patient to comply with scheduled visits, drug
             administration plan, protocol specified laboratory tests, other study procedures and
             study restrictions

          -  Evidence of personally signed informed consent indicating that the subject is aware of
             the life-threatening nature of the disease and has been informed on the procedures to
             be followed, the experimental nature of the therapy, alternative, potential risks and
             discomforts, potential benefits and other pertinent aspects of study participation.

        Exclusion Criteria:

          -  Patients requiring mechanical ventilation (intubation or Bi-PAP) at the time
             randomization.

          -  Patients receiving any investigational drugs other than drugs or therapies to treat
             COVID-19, with the exception of investigational immune-modulatory drugs as per section
             5.4.

          -  Pregnant women are excluded from this study because duvelisib is agent with the
             potential for teratogenic or abortifacient effects. Because there is an unknown but
             potential risk for adverse events in nursing infants secondary to treatment of the
             mother with duvelisib, breastfeeding should be discontinued before starting study drug
             and breastfeeding should not be resumed until at least 1 month after last dose of
             study drug.

          -  Clinical suspicion that the etiology of acute illness (acute decompensation) is
             primarily due to a condition other than COVID-19

          -  Known contraindication to duvelisib

          -  Patients with hepatic cirrhosis as defined by symptomatic liver dysfunction; liver
             fibrosis by biopsy; ALT &gt; 5 times ULN, AST&gt; 5 times ULN, or bilirubin &gt; 3 times ULN.

          -  Patients with autoimmune diseases or patients on chronic immunosuppressive medications
             at the time of hospital admission or screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund Waller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edmund Waller, MD, PhD</last_name>
    <phone>404-778-1900</phone>
    <email>ewaller@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Aneesh Mehta, MD</last_name>
      <phone>404-727-8435</phone>
      <email>aneesh.mehta@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Aneesh Mehta, MD</last_name>
      <phone>404-727-8435</phone>
      <email>aneesh.mehta@emory.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Edmund Waller</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The researchers plan to share individual participant data including participant status ordinal score at baseline and end of treatment, study drug allocation, duration of treatment, and survival status at Day 60.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be made available for sharing at the conclusion of the study and will be available for one year.</ipd_time_frame>
    <ipd_access_criteria>Data will be available for sharing with academic or pharmaceutical investigators for analyses including comparison of DAMPEN-CI results with those from other drug trials in similar patient cohorts. Researchers wishing to use data should email the investigators of DAMPEN-Cl. A summary of the research plan will be required prior to release of the DAMPEN-CI data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

